免疫检查点抑制剂相关心肌炎诊疗进展

Advances in the management of immune checkpoint inhibitor-associated myocarditis

免疫检查点抑制剂(immune checkpoint inhibitor,ICI)是肿瘤治疗的一大突破,在临床应用日益广泛。ICI相关心肌炎是ICI药物的罕见不良反应之一,病死率较高。尽管国内外均报道了该不良反应的治疗经验和指南,但部分医生在临床工作中仍存在认知不足、监管评估方案缺乏等问题。故本文对ICI相关心肌炎发病机制、诊断、治疗策略进行综述,以提高肿瘤科及心脏科医师的认识。

Immune checkpoint inhibitors(ICI) are a major breakthrough in oncology treatment and are increasingly used in clinical practice.ICI-associated myocarditis is one of the rare adverse reactions to ICI drugs,with a high mortality rate.Guidelines for treating this adverse reaction have been written both domestically and internationally at home and abroad.However,there is still a lack of awareness and reliable regulatory assessment protocols in clinical work.Therefore,this article reviews the pathogenesis,diagnosis,and treatment strategies of ICI-associated myocarditis in order to raise the awareness of oncologists and cardiologists.